VRTX Insider Trading

Insider Ownership Percentage: 0.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $30,955,261.94

Vertex Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Vertex Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Vertex Pharmaceuticals Share Price & Price History

Current Price: $492.42
Price Change: Price Increase of +1.95 (0.40%)
As of 04/23/2025 05:00 PM ET

This chart shows the closing price history over time for VRTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$492.42Closing price on 04/23/25:

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VRTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.32Bbought$493MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50B$0$50BTotal InflowsTotal Outflows
Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More on Vertex Pharmaceuticals

Today's Range

Now: $492.42
Low: $484.97
High: $498.41

50 Day Range

MA: $488.48
Low: $459.00
High: $513.76

52 Week Range

Now: $492.42
Low: $377.85
High: $519.88

Volume

1,247,179 shs

Average Volume

1,324,120 shs

Market Capitalization

$126.45 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?

Vertex Pharmaceuticals' top insider shareholders include:
  1. Reshma Kewalramani (CEO)
  2. Stuart A Arbuckle (COO)
  3. Amit Sachdev (EVP)
  4. Ourania Tatsis (EVP)
  5. Carmen Bozic (CMO)
  6. Charles F Wagner Jr (CFO)
  7. Jeffrey M Leiden (Chairman)
  8. Bruce I Sachs (Director)
  9. Bastiano Sanna (EVP)
  10. David Altshuler (EVP)
  11. Edward Morrow Atkinson III (EVP)
  12. Jonathan Biller (EVP)
  13. Kristen Ambrose (CAO)
  14. Sangeeta N Bhatia (Director)
Learn More about top insider investors at Vertex Pharmaceuticals.

Who are the major institutional investors of Vertex Pharmaceuticals?

Vertex Pharmaceuticals' top institutional investors include:
  1. GAMMA Investing LLC — 0.94%
  2. Rhumbline Advisers — 0.18%
  3. Chevy Chase Trust Holdings LLC — 0.17%
  4. Manning & Napier Advisors LLC — 0.09%
  5. Assenagon Asset Management S.A. — 0.08%
  6. Handelsbanken Fonder AB — 0.08%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.

Which major investors are selling Vertex Pharmaceuticals stock?

Within the previous quarter, VRTX stock was sold by these institutional investors:
  1. Assenagon Asset Management S.A.
  2. Robeco Institutional Asset Management B.V.
  3. Handelsbanken Fonder AB
  4. Moran Wealth Management LLC
  5. Birch Hill Investment Advisors LLC
  6. Janney Montgomery Scott LLC
  7. Greenwood Capital Associates LLC
  8. PKO Investment Management Joint Stock Co
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
  1. Reshma Kewalramani (CEO)
  2. Stuart A Arbuckle (COO)
  3. Amit Sachdev (EVP)
  4. Ourania Tatsis (EVP)
  5. Carmen Bozic (CMO)
  6. Charles F Wagner Jr (CFO)
  7. Jeffrey M Leiden (Chairman)
  8. Bruce I Sachs (Director)
  9. Bastiano Sanna (EVP)
Learn More investors selling Vertex Pharmaceuticals stock.

Which major investors are buying Vertex Pharmaceuticals stock?

During the previous quarter, VRTX stock was acquired by institutional investors including:
  1. GAMMA Investing LLC
  2. Manning & Napier Advisors LLC
  3. Congress Asset Management Co.
  4. SG Americas Securities LLC
  5. MassMutual Private Wealth & Trust FSB
  6. Rhumbline Advisers
  7. Asset Management One Co. Ltd.
  8. CCM Investment Advisers LLC